Warfarin therapy: in need of improvement after all these years.
about
CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosingManaging anticoagulation for atrial fibrillation: current issues and future strategiesClinical Pharmacokinetics and Pharmacodynamics of Lenalidomide.Warfarin overdose: a 25-year experience.Satisfaction with and adherence to warfarin treatment: A cross-sectional study among Sudanese patients.A Proposal for an Individualized Pharmacogenetic-Guided Warfarin Dosage Regimen for Puerto Rican Patients Commencing Anticoagulation Therapy.A review of a priori regression models for warfarin maintenance dose prediction.Warfarin therapeutic monitoring: is 70% time in the therapeutic range the best we can do?Emergency management of bleeding associated with old and new oral anticoagulants.Potential Underprediction of Warfarin Drug Interaction From Conventional Interaction Studies and Risk Mitigation: A Case Study With Epacadostat, an IDO1 Inhibitor.Warfarin Dosing Algorithms Underpredict Dose Requirements in Patients Requiring ≥7 mg Daily: A Systematic Review and Meta-analysis.Multiple doses of sitagliptin, a selective DPP-4 inhibitor, do not meaningfully alter pharmacokinetics and pharmacodynamics of warfarin.The effectiveness and safety of fixed low-dose prothrombin complex concentrates in patients requiring urgent reversal of warfarin.Telephone versus office-based management of warfarin: impact on international normalized ratios and outcomes.Novel venous thromboembolic disease (VTED) prophylaxis for total knee arthroplasty-aspirin and fish oil.Evaluation of pharmacokinetic and pharmacodynamic interactions when lenalidomide is co-administered with warfarin in a randomized clinical trial setting.The pharmacoepigenomics informatics pipeline defines a pathway of novel and known warfarin pharmacogenomics variants.Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor.Signals of bleeding among direct-acting oral anticoagulant users compared to those among warfarin users: analyses of the post-marketing FDA Adverse Event Reporting System (FAERS) database, 2010-2015.Response to Letter to the Editor: Factors Affecting Warfarin Related Knowledge and INR Control of Patients Attending Physicians and Pharmacists’ Managed Anticoagulation Clinics
P2860
Q24641999-B9136E5C-8C0B-491D-9FB3-4C8C9EB3C11EQ26991728-7901286B-763A-44F8-ACFF-C5A90F49B3A4Q33433453-BF8154D1-13F9-4198-9719-B38D24E86D53Q33754932-2372B10D-92E4-4586-B352-9437E54D4381Q33811036-603BE769-F5EB-4793-AA03-C8F032697192Q34273608-E41D5BE7-CDED-4C0F-BCD8-A1DAEB98200EQ34690708-4977E843-7268-49C0-88C7-47173681A4A9Q37968617-8B0FF456-72C7-4431-BDC3-6B753331CBD8Q38027479-4456B0D0-4A48-40F0-A697-4DFCDD11A6AEQ38893410-0C13C743-6D40-461F-A339-4BD01BC03F53Q38979667-EDC3BA04-9312-47A2-A83F-6DA307FB2C0EQ43270616-5395912E-03FA-4AB1-9700-2059CAE9C540Q44241618-8A635282-601A-44F9-876F-17885F987321Q46762572-D213DA1C-A459-4C79-9E25-717C7456D578Q47390382-0225CD66-8B43-49CE-8886-36EFA8C5BDDEQ49048515-B7C9B317-2804-41DC-840B-807128FB5973Q50199930-3AA59D65-1762-4C71-89E3-94F24FC718DEQ52838335-66C9F758-3CE3-4308-A66D-17BAE3352D2DQ55265837-6CAC409F-5B39-456E-9036-329E7E7BAA3EQ58073890-FF5694ED-6D4B-4C4A-BB24-44A4188EA087
P2860
Warfarin therapy: in need of improvement after all these years.
description
2008 nî lūn-bûn
@nan
2008 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Warfarin therapy: in need of improvement after all these years.
@ast
Warfarin therapy: in need of improvement after all these years.
@en
type
label
Warfarin therapy: in need of improvement after all these years.
@ast
Warfarin therapy: in need of improvement after all these years.
@en
prefLabel
Warfarin therapy: in need of improvement after all these years.
@ast
Warfarin therapy: in need of improvement after all these years.
@en
P2860
P356
P1476
Warfarin therapy: in need of improvement after all these years.
@en
P2093
Stephen E Kimmel
P2860
P304
P356
10.1517/14656566.9.5.677
P407
P577
2008-04-01T00:00:00Z